Last reviewed · How we verify
Pharmacotherapies for Smoking Cessation
Pharmacotherapies for Smoking Cessation is a Small molecule drug developed by National Institute on Drug Abuse (NIDA). It is currently FDA-approved.
At a glance
| Generic name | Pharmacotherapies for Smoking Cessation |
|---|---|
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- Enhancing Smoking Cessation for African American People Everywhere (PHASE2)
- A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pharmacotherapies for Smoking Cessation CI brief — competitive landscape report
- Pharmacotherapies for Smoking Cessation updates RSS · CI watch RSS
- National Institute on Drug Abuse (NIDA) portfolio CI
Frequently asked questions about Pharmacotherapies for Smoking Cessation
What is Pharmacotherapies for Smoking Cessation?
Pharmacotherapies for Smoking Cessation is a Small molecule drug developed by National Institute on Drug Abuse (NIDA).
Who makes Pharmacotherapies for Smoking Cessation?
Pharmacotherapies for Smoking Cessation is developed and marketed by National Institute on Drug Abuse (NIDA) (see full National Institute on Drug Abuse (NIDA) pipeline at /company/national-institute-on-drug-abuse-nida).
What development phase is Pharmacotherapies for Smoking Cessation in?
Pharmacotherapies for Smoking Cessation is FDA-approved (marketed).